Millions of Americans suffer from opioid addiction, while millions more suffer from chronic debilitating pain. Doctors often work to decipher the difference with limited insight into patients’ psychological conditions. Priska™ is a best-in-class online assessments platform developed by renowned pain specialist and psychologist Dr. Michael Lewandowski. Priska provides practitioners with data for understanding the experience and mental health of patients, helping to ensure they administer the best possible care.
Additionally, laws are being enacted in many states to ensure doctors better identify patients with the highest potential risk of addiction prior to prescribing certain pain medications. In 2017, Nevada passed ordinance AB 474, which requires all practitioners prescribing schedule II, III or IV controlled substances to “(conduct) an evaluation and risk assessment… assessing the mental health and risk of abuse, dependency and addiction of the patient using methods supported by peer-reviewed scientific research and validated by a nationally recognized organization.” Under this new law, doctors are also required to administer additional addiction risk assessments every 90 days for patients requiring extended treatment. Priska™ provides an easy-to-use, cloud-based solution to address these requirements.
About Priska™
Priska™ is designed to provide assessment data associated with a patient’s risk for opioid abuse, as well as other mental health conditions. The Opioid Risk Tool assessment consists of a 5-question survey and fits each patient into one of three risk categories: low risk, moderate risk or high risk. The peer-reviewed tool is highly trusted and widely used. Priska brings the peer-reviewed and nationally-recognized work of Dr. Lynn Webster into the easily accessible SaaS-based solution. The assessment gives doctors the insights necessary to ease the burdens associated in complying with the emerging legal framework in and around pain management. Webster LR. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Medicine. 20005;6(6):432-442. Used With Permission.
Disclaimer
Screening is used to identify the likelihood a patient is at risk of having a specific health condition. However, it does not provide a diagnosis and should not be used in lieu of or absent counsel from a medical professional. Priska™ does not function to deliver a complete and full diagnosis of a patient’s mental health or any other condition. Priska is designed to be one part of an overall practitioner’s assessment toolkit, and requires review and consideration by an accredited practitioner. Pendrake does not and cannot guarantee, warrant, or certify that use of the Priska platform and assessments accurately indicate a patient’s risk or mental condition, or the veracity of a patient’s responses. Priska™ Tools should be used as an ancillary item to help further inform practitioners who write pain management protocols. Doctors should however use every tool available to them, such as abuse-deterrent opioids, lock boxes, safer packaging, government-run prescription monitoring programs that identify people accessing multiple prescribers, and state-of-the-art drug tests.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171213005585/en/
Contacts:
Brooke Brumfield, 530-414-6259
brooke@brookebrumfield.com
